SMS Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/oktszczhdjstv1wb504bbugh.pdf

Key Takeaways


Performance & Margin Drivers

Potluri: "if we have not backward integrated, like we've not taken this call of backward integration a couple of years back, we would have probably been in a very bad situation now because of the current market scenarios, because of price escalations, we wouldn't have been able to survive in the market."

Growth Pipeline: Brownfield, Peptides & CDMO


Related-Party Ecosystem


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15% growth; potential to exceed if external environment stabilizes and logistics improveFY27
EBITDA marginImprove upon FY26's 20%; target 22%FY27
Brownfield expansion completion~₹280 crores total investment, ₹130 crores already invested; completion and incremental revenues thereafterCompletion by Mar FY27; revenues from FY28
DMF/CEP filings10 filingsFY27
DMF/CEP filingsFurther 10 filingsFY28
JV product commercializationFive new productsFY27
Peptides commercial roadmap clarityGreater clarity expectedAfter next 2 quarters
CDMO comprehensive updateBetter position to provide updateAfter next 2 quarters

Key Metrics

MetricQ4 FY26
Revenue₹238 cr
Full-year revenue₹887 cr, +13% YoY
Gross profit₹81 cr
Full-year gross profit₹303 cr, +14% YoY; gross margin at 34%
EBITDA₹40 cr, margin at 17%
Full-year EBITDA₹171 cr, +23% YoY; margin at 20%
PAT₹33 cr, including ₹12 cr from associate VKT Pharma; excluding that, PAT at ₹21 cr
Full-year PAT₹102 cr, +47% YoY, including ₹14 cr from VKT Pharma; excluding VKT Pharma, PAT grew 28% to ₹88 cr
FY27 revenue growth guidance15%, with potential to exceed if external environment stabilizes
FY27 EBITDA margin target22%, aiming to improve upon FY26 margin of 20% and reach historical high
Installed capacity (post capex)800 metric tons per month, increasing from 500 tons; completion by March FY27
Current capacity utilization~80%
High-value product share47% of total sales, expected to reach around 60%
Export share70% of business, expected to remain in 70–75% range
Ibuprofen revenue contribution~20% of total revenue